NCT01374373 - Epoetin Alfa (Hemax®) Phase IV Study in Chemotherapy Induced Anemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions

Antineoplastic Chemotherapy Induced Anemia

Interventions

BIOLOGICAL

Epoetin alfa

Epoetin alfa 40.000-60.000 IU/week subcutaneously that will be controlled and up or down titrated every 2 weeks according to the currently approved prescription guidance for a total of 12 weeks of treatment with Co administration of oral ferrous sulfate 200mg BID and oral folic acid 5mg QD

Trial Locations (3)

Unknown

Centro Oncologico de Investigaciones Buenos Aires, Berazategui

Centro de Medicina Integral e Investigación Clínica, Buenos Aires

CP 1824

Hospital Zonal Especializado en Oncología de Lanus, Lanús Este